Moteur de recherche d’entreprises européennes
Financement de l’UE (2 497 841 €) : Comprendre le développement du cancer chez les porteurs de la mutation BRCA 1/2 pour améliorer la détection précoce et le contrôle des risques Hor04/07/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Comprendre le développement du cancer chez les porteurs de la mutation BRCA 1/2 pour améliorer la détection précoce et le contrôle des risques
Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.
| Karolinska Institutet | 212 000 € |
| Universitaet Innsbruck | 1 115 793 € |
| University College London | 856 797 € |
| University College London Hospitalsnhs Foundation Trust | 233 251 € |
| Vseobecna Fakultni Nemocnice V Praze | 80 000 € |
https://cordis.europa.eu/project/id/742432
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
